<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Regulatory News:
 
 
 Mauna Kea Technologies MKEA (Euronext: MKEA, OTCQX: 
 MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser 
 endomicroscopy (CLE) platform, today announced a new peer-reviewed <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbmjopengastro.bmj.com%2Fdoi%2Fabs%2F10.1136%2Fbmjgast-2016-000105%3Faf%3DR&amp;esheet=51519581&amp;newsitemid=20170302006042&amp;lan=en-US&amp;anchor=publication&amp;index=1&amp;md5=454a5b67cf83dbcdc65b388c5d23a194" rel="nofollow" rel="nofollow">publication</a> 
 from the Singapore Gastric Cancer Consortium1 highlighting 
 the excellent results utilizing Cellvizio in improving diagnostic yield 
 in gastric cancer, including the need for two-thirds fewer biopsies to 
 confirm the presence of disease. The publication includes a 
 meta-analysis of studies utilizing CLE with Cellvizio in gastric 
 diseases, demonstrating superior results compared to conventional 
 imaging modalities also evaluated in the study, including 
 chromoendoscopy and narrow band imaging.
 
 
 Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea 
 Technologies, said, "This publication highlights a compelling 
 opportunity to utilize Cellvizio to reduce uncertainties in the 
 diagnosis, treatment and monitoring of patients with gastric cancer and 
 disease. It clearly demonstrates the improved diagnostic performances, 
 both in terms of identifying disease and guiding biopsies, when 
 utilizing CLE in gastric cancer as compared to standard imaging 
 technologies. Gastric cancer is the third leading cause of cancer death 
 worldwide and is the most prevalent cancer in the Asia-Pacific region. 
 We look forward to raising awareness of these powerful results and to 
 expanding Cellvizio adoption to benefit more patients around the world."
 
 
 Key data from the meta-analysis performed on CLE and gastric diseases 
 include:
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 85% sensitivity and 99% specificity in detecting and diagnosing polyps 
 and neoplastic lesions
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 94% sensitivity and 95% specificity in detecting and diagnosing 
 gastritis and gastric metaplasia
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 86% sensitivity and 93% specificity in detecting and diagnosing H. 
 pylori-related gastritis
 </li>
 </ul>
 
 In this same paper, the authors reminded their local experience 
 resulting in following results:
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Two-third fewer biopsies required to confirm gastric intestinal 
 metaplasia compared to conventional imaging
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Higher diagnostic yield of 65.7% for gastric intestinal metaplasia, 
 compared to 15.7% with conventional imaging (p&lt;0.001)
 </li>
 </ul>
 
 Almost one million new cases of stomach cancer were estimated to have 
 occurred in 2012, making it the fifth most common malignancy in the 
 world, after cancers of the lung, breast, colorectum and prostate. Half 
 the world total occurs in Eastern Asia (mainly in China). Stomach cancer 
 is the third leading cause of cancer death in both sexes worldwide 
 (723,000 deaths, 8.8% of the total). The highest estimated mortality 
 rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in 
 women)2.
 
 
 In their summary table, the authors considered CLE as a mature 
 technology and not necessitating additional clinical evidence in this 
 application, and highlighted the importance of adequate training for 
 accurate CLE diagnosis.
 
 
 About Mauna Kea Technologies
 
 
 Mauna Kea Technologies is a global medical device company focused on 
 eliminating uncertainties related to the diagnosis and treatment of 
 cancer and other diseases thanks to real time in vivo microscopic 
 visualization. The Company's flagship product, Cellvizio, has received 
 clearance to sell a wide range of applications in more than 40 
 countries, including the United States, Europe, Japan, China, Canada, 
 Brazil and Mexico. For more information on Mauna Kea Technologies, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maunakeatech.fr%2F&amp;esheet=51519581&amp;newsitemid=20170302006042&amp;lan=en-US&amp;anchor=www.maunakeatech.com&amp;index=2&amp;md5=6c526d2f59f5829d2b7b2197aec66deb" rel="nofollow" rel="nofollow">www.maunakeatech.com</a>
 
 
 1 Publication by JWJ Lee, LG Lim and KG Yeoh. Advanced 
 endoscopic imaging in gastric neoplasia and preneoplasia, BMJ Open 
 Gastro, 2017 2 World Health Organization, Globocan 2012: <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fglobocan.iarc.fr%2Fold%2FFactSheets%2Fcancers%2Fstomach-new.asp&amp;esheet=51519581&amp;newsitemid=20170302006042&amp;lan=en-US&amp;anchor=http%3A%2F%2Fglobocan.iarc.fr%2Fold%2FFactSheets%2Fcancers%2Fstomach-new.asp&amp;index=3&amp;md5=1b1970279612e4f803cd3d246e6cf740" rel="nofollow" rel="nofollow">http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp</a>
 
 
 Disclaimer
 
 
 This press release contains forward-looking statements concerning Mauna 
 Kea Technologies and its activities. Such forward looking statements are 
 based on assumptions that Mauna Kea Technologies considers to be 
 reasonable. However, there can be no assurance that the anticipated 
 events contained in such forward-looking statements will occur. 
 Forward- looking statements are subject to numerous risks and 
 uncertainties including the risks set forth in the registration document 
 of Mauna Kea Technologies registered by the French Financial Markets 
 Authority (Autorité des marchés financiers (AMF)) on June 13, 2016 under 
 number R.16-054 and available on the Company&#39;s website (<a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maunakeatech.fr%2F&amp;esheet=51519581&amp;newsitemid=20170302006042&amp;lan=en-US&amp;anchor=www.maunakeatech.com&amp;index=4&amp;md5=6e2ed6014128cbd79fb18f560c22476c" rel="nofollow" rel="nofollow">www.maunakeatech.com</a>), 
 and to the development of economic situation, financial markets, and the 
 markets in which Mauna Kea Technologies operates. The forward-looking 
 statements contained in this release are also subject to risks unknown 
 to Mauna Kea Technologies or that Mauna Kea Technologies does not 
 consider material at this time. The realization of all or part of these 
 risks could lead to actual results, financial conditions, performances 
 or achievements by Mauna Kea Technologies that differ significantly from 
 the results, financial conditions, performances or achievements 
 expressed in such forward-looking statements. This press release and the 
 information it contains do not constitute an offer to sell or to 
 subscribe for, or a solicitation of an order to purchase or subscribe 
 for, Mauna Kea Technologies shares in any country.
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170302006042r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170302006042/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170302006042/en/</a></body></html>

Press Releases

Mauna Kea Technologies: Superiority of Endomicroscopy for the Diagnosis of Gastric Cancer Highlighted in a Peer-Reviewed Publication Comparing Advanced Imaging Technologies 

MKEAY

Mauna Kea Technologies: Superiority of Endomicroscopy for the Diagnosis of Gastric Cancer Highlighted in a Peer-Reviewed Publication Comparing Advanced Imaging Technologies


With over $2 billion in assets, Texas Partners Bank celebrates 17 years of powering partnerships in Central Texas communities.


Southwest Bancshares, Inc., the bank holding company for Texas Partners Bank, today

Southwest Bancshares, Inc., Announces Texas Partners Bank as the Regional Bank Brand


Prudent financial policies, comprehensive resource planning in district&#39;s new biennial budget cited as foundation of ratings from S&amp;P, Moody&#39;s


A week after its governing board adopted a financially responsible

Two Top Rating Agencies Reaffirm Metropolitan&#39;s Strong Credit Ratings

TYO:4502


− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn&#39;s Disease


Takeda ((

U.S. FDA Approves Subcutaneous Administration of Takeda&#39;s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn&#39;s Disease

MATV


Mativ Holdings, Inc. (NYSE:MATV) today announced it will release first quarter 2024 financial results on May 8, 2024, after the market closes.


A conference call to discuss these results has been scheduled for 8:30

Mativ Announces Conference Call to Discuss First Quarter 2024 Results

Glancy Prongay &amp; Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Primerica, Inc. (PRI) on Behalf of Investors


Skyhigh Security also recognized in the 2024 Gartner Critical Capabilities Report for SSE


Skyhigh Security today announced it was named a Visionary in the 2024 Gartner® Magic Quadrant™ for the second year